Incannex (formerly Impression) Healthcare has partnered with The Alfred Hospital to conduct the IHL-42X clinical trial for Obstructive Sleep Apnoea (‘OSA’)

2020-07-09 04:18:06 (AET) by Ring Zhang   250


Incannex Healthcare Limited (ASX: IHL) announced a partnership with Melbourne-based hospital The Alfred to advance its IHL-42X Phase 2b clinical trial for Obstructive Sleep Apnoea diagnosed in adults.

Incannex Healthcare Limited (ASX: IHL) announced a partnership with Melbourne-based hospital The Alfred to advance its IHL-42X Phase 2b clinical trial for Obstructive Sleep Apnoea diagnosed in adults.

The potential development of IHL-42X is significant as it is attempting to address the market in OSA that is estimated to be worth at least US$10billion per annum. At the present time there is NO existing pharmacological (drug) treatment for OSA and IHL-42X represents a world first novel combination drug trial into the treatment of the condition.

Professor Terence O’Brien, who is a World-known clinician and specialist in neurology and clinical pharmacology with extensive experience, was named the Principal Investigator of the trial to lead the study team.

Professor O’Brien was formerly The University of Melbourne’s James Stewart Chair of Medicine and Head of the Department of Medicine at the Royal Melbourne Hospital (2008-17), with expertise in epilepsy and related brain diseases, including traumatic brain injury, brain tumours and neurodegenerative diseases..

The upcoming Phase 2b trial will be based at The Alfred Hospital sleep clinic. A baseline sleep clinic visit will confirm patient OSA diagnoses and establish baseline levels for Apnoea Hypopnea Index (“AHI”) as measured by an overnight polysomnography, and receive treatment with IHL-42X.

The primary endpoint of the clinical trial is the improvement in AHI as measured by an overnight polysomnography. Secondary outcomes include the following:

  • Reduction in oxygen desaturation index (ODI)
  • Daytime somnolence measured by the Epworth Sleepiness Scale
  • Improvement in mood as measured by the POMS (Profile of Moods State), and well-being as measured by the Short Form 36
  • Safety of the IHL-42X combination will be established through adverse event monitoring.

The Alfred Health Ethics Committee will be responsible for the ethical design, review and conduct of human research of the trial. Meetings of the Ethics Committee occur periodically and IHL will register its trial for review by the next registration deadline, which is the 27th of July 2020.

IHL will endeavour to supply IHL-42X for sale in Australia under the Special Access Scheme for unregistered medicinal cannabis products, alongside its existing range of cannabinoid oils and CBD Inhaler. IHL will also proceed to the second Phase 2 ‘Factorial’ clinical trial as it compiles the necessary information for a 505(b)(2) new drug application. Achieving FDA registration would entail market exclusivity over their unique product and acceptance by the medical community.

To ensure the IHL-42X clinical trial meets the requirements of the FDA in relation to site management, data collection, analysis, and safety monitoring, the company has entered into a contract with a full-service Contract Research Organisation Novotech.

Novotech was estabbished in 1996 and has offices in 11 locations across the Asia Pacific region. Novotech acquired Clinical Network Services (CNS), an integrated service group focused on product development headquartered in Australia with offices in New Zealand, the UK and the USA. Novotech has been instrumental in the success of over 1000 Phase I - IV clinical trials for biotechnology companies.

Stock Price Chart

text
【Check out more IHL stock price at here


Source: IHL ASX announcement Incannex Partners with The Alfred and Novotech on IHL-42X Clinical Program for Obstructive Sleep Apnoea


標簽:

聲明:這些資訊屬於事實信息,僅供參考,不應被視為投資建議或用於投資決策

版權所有,轉載需注明出處:61 澳洲財經資訊 news.61financial.com.au

商務合作請聯系 support@61financial.com.au


61 澳洲財經資訊郵件訂閱服務,每日為您推薦最新澳洲財經資訊


推廣

cover
61 i澳股 - 澳洲股票投資機會訂閱服務

61 Financial 全新的 i澳股 (istocks) 訂閱服務已經上線!i澳股提供精選關注股列表,61澳股分析團隊會從ASX 2000多家公司裏精選最有潛力的澳洲股票,毫不保留地分享給用戶。另外,用戶可以定制化文章,把想看的個股或行業報告告訴我們,分析團隊將會根據用戶的需求撰寫分析報告。無論你是澳股大神或是新手,這個訂閱服務將會幫助您深入了解澳洲股票,提供一個思路讓用戶投資時更得心應手。

cover
鈾釩礦商Delecta的REX礦返回了高品位鈾釩結果

專注於美國鈾釩項目的澳洲勘探商Delecta Limited (ASX: DLC) 早間宣布其位於科羅拉多州的REX鈾釩項目采樣計劃的優異初步測定結果。鈾品位高達5280ppm U3O8(氧化鈾),釩品位高達13600ppm V2O5(氧化釩)。

相關文章

cover
Incannex achieved record sales in June quarter with more clinical results from multiple studies expected in the current quarter

Cannabinoid Drug Developer Incannex Healthcare (ASX: IHL) reported record cash receipts of $670K, representing a 97% increase over the last corresponding period. The reports details significant progress and of more news flow to come in the current quarter from across its range of clinical programs that it is working towards achieving FDA registration and market exclusivity.